Continuation treatment with escitalopram reduces body dysmorphic disorder relapse

In what is believed to be the first relapse prevention study in body dysmorphic disorder (BDD), researchers found that 6 months of continuation treatment with escitalopram resulted in fewer relapses and an increased time to relapse when compared with placebo. However, patients receiving escitalopram in the study's continuation phase did not see significant improvement in psychosocial functioning or quality of life when compared with placebo patients, the researchers reported.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: What's New in Research Source Type: research